| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30060134 | HIV | ENSG00000109163.7 | protein_coding | GNRHR | No | No | 2798 | P30968 |
| TVIS30060135 | HIV | ENSG00000109163.7 | protein_coding | GNRHR | No | No | 2798 | P30968 |
| TVIS20009946 | HPV | ENSG00000109163.7 | protein_coding | GNRHR | No | No | 2798 | P30968 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GNRHR |
|---|---|
| DrugBank ID | DB06699 |
| Drug Name | Degarelix |
| Target ID | BE0000203 |
| UniProt ID | P30968 |
| Regulation Type | antagonist |
| PubMed IDs | 20110043; 20053189; 19450172; 15705170 |
| Citations | Steinberg M: Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. 2009;31 Pt 2:2312-31. doi: 10.1016/j.clinthera.2009.11.009.@@Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x.@@Anderson J: Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol. 2009 May;5(4):433-43. doi: 10.2217/fon.09.24.@@Samant MP, Miller C, Hong DJ, Koerber SC, Croston G, Rivier CL, Rivier JE: Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine. J Pept Res. 2005 Feb;65(2):284-91. |
| Groups | Approved |
| Direct Classification | Polypeptides |
| SMILES | CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O |
| Pathways | |
| PharmGKB | PA165958373 |
| ChEMBL | CHEMBL415606 |
